33 results
8-K
EX-1.1
CGTX
Cognition Therapeutics Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:07pm
by such tax returns (whether or not such amounts are shown as due on any tax return), (B) no deficiency assessment with respect to a proposed adjustment
424B5
CGTX
Cognition Therapeutics Inc
13 Mar 24
Prospectus supplement for primary offering
4:04pm
of Aβ monomers and a positive trend on cognitive function as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog … as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate
424B5
CGTX
Cognition Therapeutics Inc
11 Mar 24
Prospectus supplement for primary offering
4:06pm
function as measured by the Alzheimer’s Disease Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We … Assessment Scale-Cognitive Subscale, or ADAS-Cog, in patients receiving CT1812 compared to placebo. We anticipate completing enrollment in 2023 with top
424B4
pxz448mc
8 Jan 24
Prospectus supplement with pricing info
4:11pm
8-K
EX-10.1
w5hzzevyoaw ngjq
23 Dec 22
Entry into a Material Definitive Agreement
4:24pm
S-3
wj7tmjo4cro0t vzl
23 Dec 22
Shelf registration
4:16pm
S-3
EX-1.2
ke0j0e 8lg
23 Dec 22
Shelf registration
4:16pm
8-K
EX-1.1
3trlb262ffx6op91
14 Nov 22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
8:00am
424B4
0sy5eny0iw294v0
14 Nov 22
Prospectus supplement with pricing info
6:02am
DRS
cnxa9203f8m
20 Oct 22
Draft registration statement
12:00am
8-K
EX-99.1
qfdhi
29 Aug 22
Developing disease- modifying medicines for degenerative disorders August 2022
6:36am
8-K
EX-99.1
sfb1tukky
16 Jun 22
Regulation FD Disclosure
7:08am
DEF 14A
wis pxkck51nl8beaqw
25 Apr 22
Definitive proxy
5:28pm